Introduction to the Complement System and CD59

The complement system is a critical part of innate immunity that protects the body against pathogens, abnormal cells, and immune complexes. Complement activation occurs through two interconnected pathways known as the classical pathway and the alternative pathway. The classical pathway is primarily initiated by immune complexes containing IgG or IgM antibodies, whereas the alternative pathway can be activated by microbial polysaccharides, endotoxins, cobra venom factor, and aggregated IgA molecules.

Both pathways ultimately generate C3 convertase, an enzyme complex responsible for producing large quantities of C3b. This process triggers a cascade of terminal complement reactions that lead to the assembly of the membrane attack complex (MAC), composed of complement proteins C5b, C6, C7, C8, and multiple C9 molecules. Formation of the MAC on cell membranes creates transmembrane pores that induce osmotic lysis and cell destruction.

Under normal physiological conditions, host cells are protected from unintended complement-mediated injury through several membrane-associated complement regulatory proteins. Among these protective molecules, decay accelerating factor (DAF/CD55), membrane cofactor protein (MCP/CD46), and complement receptor 1 (CR1/CD35) regulate C3/C5 convertase activity. In contrast, homologous restriction factor (HRF) and protectin (CD59) specifically inhibit MAC formation.

CD59 has emerged as one of the most important regulators of complement-mediated cytotoxicity. Functional studies and investigations of paroxysmal nocturnal hemoglobinuria (PNH), a disorder characterized by increased sensitivity of erythrocytes to complement attack, demonstrated that CD59 acts as a primary inhibitor of complement-induced cell lysis. CD59 blocks the terminal stage of MAC assembly by interacting with C8 and C9 components. Although the initial C5b-8-C9 complex can still form in the presence of CD59, the protein prevents the addition of further C9 molecules, thereby stopping pore formation and protecting cells from osmotic destruction.

Because of its essential role in complement regulation and tumor immune resistance, CD59 has become an important focus in cancer biology and immunotherapy research.

Structural Characteristics of CD59

Gene Organization

The CD59 gene is located on chromosome 11p14-p13 and is composed of four exons separated by large intronic regions. Exon 1 contains part of the untranslated region, while exons 2 through 4 encode the signal peptide, mature protein sequence, and glycosyl-phosphatidylinositol (GPI) anchoring region.

The promoter region of CD59 is GC-rich and lacks traditional TATA and CAAT motifs, but it contains SP1 transcription factor binding sites that regulate gene expression. Multiple CD59 mRNA transcripts of different sizes have been identified due to the use of alternative polyadenylation sites. These transcripts are expressed in both normal and malignant tissues.

Protein Structure

The mature CD59 protein consists of 77 amino acids and is attached to the outer cell membrane through a GPI anchor. The precursor protein contains:

  • An N-terminal signal peptide required for endoplasmic reticulum transport
  • A central mature extracellular domain
  • A C-terminal hydrophobic sequence responsible for GPI-anchor attachment

Following synthesis, the mature glycosylated protein is transported to the plasma membrane where it becomes highly mobile within lipid microdomains such as caveolae and detergent-resistant membrane regions.

Glycosylation

CD59 contains both N-linked and O-linked glycosylation sites that generate multiple glycoforms. Although glycosylation appears to have minimal effects on protein folding or complement inhibitory activity, it may influence:

  • Membrane distribution
  • Protein orientation
  • Resistance to proteolytic degradation
  • Interaction efficiency with MAC proteins

GPI Anchor Function

The GPI anchor is essential for membrane attachment and lateral mobility of CD59. This mobility enables efficient interaction with MAC components during complement attack.

In addition to membrane anchoring, the GPI structure participates in intracellular signaling and allows soluble forms of CD59 to reinsert into cellular membranes. Variations in GPI-anchor composition among different cell types can alter sensitivity to phosphatidylinositol-specific phospholipase C (PI-PLC), a feature observed in several tumor cell lines.

Structural Homology and Evolutionary Similarities

CD59 shares sequence homology with several GPI-anchored proteins, including:

  • Murine Ly-6 antigens
  • Snake venom neurotoxins
  • Human urokinase plasminogen activator receptor (uPAR)
  • Viral CD59-like proteins encoded by herpesvirus saimiri

Some enveloped viruses, including HIV-1, HTLV-I, and human cytomegalovirus, incorporate host-derived CD59 into their viral envelopes. This acquired CD59 protects virions against complement-mediated destruction and contributes to viral immune evasion.

Intracellular Signaling Functions of CD59

Although CD59 is primarily recognized as a complement inhibitor, increasing evidence demonstrates that it also participates in intracellular signaling pathways.

GPI-anchored proteins such as CD59 localize within cholesterol-rich membrane microdomains containing Src-family kinases and signaling molecules. Crosslinking of CD59 can trigger:

  • Calcium mobilization
  • Tyrosine phosphorylation
  • Oxidative burst activation
  • T-cell proliferation
  • Cytokine production
  • IL-2 synthesis

In T lymphocytes, CD59 cooperates with CD3/T-cell receptor complexes and enhances immune activation. These findings suggest that CD59 has both passive protective functions and active signaling roles.

Mechanisms Leading to Defective CD59 Expression

Loss of CD59 expression is strongly associated with paroxysmal nocturnal hemoglobinuria (PNH). Mutations in the PIG-A gene impair GPI-anchor biosynthesis, resulting in defective surface expression of CD59 and other GPI-anchored proteins.

Unlike CD55 deficiency, which is generally asymptomatic, complete CD59 deficiency produces severe complement-mediated hemolysis and thrombosis, highlighting the critical protective role of CD59.

Additional mechanisms responsible for reduced CD59 expression include:

  • Transcriptional defects
  • Post-transcriptional abnormalities
  • Altered protein processing
  • Defective membrane anchoring

Certain melanoma cell lines show complete absence of CD59 protein despite normal mRNA expression, suggesting defects in post-transcriptional regulation.

Distribution of CD59 in Normal Tissues

CD59 is widely distributed in hematopoietic and non-hematopoietic tissues, reflecting its role in protecting host cells from complement attack.

High CD59 expression is found on:

  • Blood cells
  • Endothelial cells
  • Epithelial tissues
  • Fibroblasts
  • Cardiomyocytes
  • Keratinocytes
  • Placental syncytiotrophoblasts
  • Spermatozoa

Lower expression occurs in tissues naturally protected from complement exposure, including:

  • Hepatocytes
  • Pancreatic islets
  • Oligodendrocytes

Strong expression during fetal development suggests a protective role in embryogenesis and reproduction.

CD59 in Non-Malignant Diseases

Abnormal CD59 expression has been reported in multiple inflammatory and ischemic disorders.

Reduced CD59 Expression

Decreased CD59 levels have been observed in:

  • Myocardial infarction
  • Ischemic kidney injury

These reductions are associated with enhanced MAC deposition and tissue injury.

Increased CD59 Expression

Upregulated CD59 expression occurs in:

  • Arthritis
  • Ulcerative colitis
  • Inflammatory tissues

This likely represents a protective host response against excessive complement-mediated inflammation.

Cytokines such as IL-1, TNF-α, IFN-γ, and signaling activators including PMA and cAMP can regulate CD59 expression depending on cell type and inflammatory context.

Soluble CD59 (sCD59)

A soluble GPI-anchored form of CD59 has been identified in several biological fluids, including:

  • Urine
  • Amniotic fluid
  • Seminal plasma
  • Cerebrospinal fluid
  • Breast milk
  • Blood serum

Soluble CD59 retains functional complement inhibitory activity and can reintegrate into cell membranes, potentially providing systemic protection against complement injury.

Studies suggest that sCD59 may associate with plasma lipoproteins and circulate throughout the bloodstream.

CD59 Expression in Human Malignancies

Extensive research demonstrates strong CD59 expression in many solid tumors, including:

  • Melanoma
  • Prostate carcinoma
  • Breast carcinoma
  • Renal cell carcinoma
  • Lung carcinoma
  • Thyroid cancer
  • Ovarian carcinoma
  • Glioblastoma
  • Colorectal carcinoma
  • Cervical carcinoma

Expression patterns are often heterogeneous and may correlate with tumor differentiation, invasiveness, or metastatic progression.

Melanoma

Most primary and metastatic melanomas strongly express CD59. Functional studies revealed that melanoma susceptibility to complement-mediated killing inversely correlates with CD59 surface expression.

Prostate Cancer

Prostate tumors and metastatic cell lines express significant levels of CD59, particularly at cell-cell junctions.

Breast Cancer

Breast carcinomas display variable but generally elevated CD59 expression compared with normal tissues.

Colorectal Cancer

CD59 expression varies substantially among colorectal tumors and may correlate with differentiation stage and metastatic status.

Functional Role of CD59 in Tumor Resistance

Tumor-associated complement activation may occur through:

  • Naturally occurring antibodies
  • Therapeutic monoclonal antibodies
  • Vaccination-induced antibodies
  • Spontaneous complement activation

However, tumor cells evade complement-mediated destruction by overexpressing complement inhibitory proteins, especially CD59.

Blocking CD59 with monoclonal antibodies or removing it from the cell surface significantly increases complement-mediated killing of tumor cells sensitized with therapeutic antibodies.

This protective effect has been demonstrated in:

  • Melanoma
  • Prostate cancer
  • Breast cancer
  • Colon carcinoma
  • Ovarian carcinoma
  • Glioblastoma

Experimental evidence strongly supports CD59 as a major resistance factor limiting the efficacy of complement-activating immunotherapies.

Regulation of CD59 Expression in Cancer Cells

 

Several agents influence CD59 expression in tumor cells.

Upregulation

Increased CD59 expression may occur after exposure to:

  • TNF-α
  • IL-1
  • IL-6
  • PMA
  • 5-Aza-2′-deoxycytidine

Enhanced CD59 expression generally reduces tumor susceptibility to complement-mediated lysis.

Downregulation

Certain compounds, such as levamisole, can decrease CD59 expression and increase complement sensitivity.

The tumor microenvironment and inflammatory mediators may therefore dynamically regulate complement resistance.

Soluble CD59 in the Tumor Microenvironment

Tumor cells can release functional soluble CD59 into the extracellular environment. Melanoma and colon carcinoma cells have been shown to secrete sCD59 capable of:

  • Rebinding to neighboring cells
  • Blocking anti-CD59 antibodies
  • Reducing complement-mediated cytotoxicity

This process may create a CD59-rich tumor microenvironment that protects both malignant and surrounding stromal cells from immune destruction.

Clinical Implications and Future Therapeutic Strategies

Current evidence indicates that CD59 plays a central role in tumor immune escape by inhibiting complement-mediated cytotoxicity.

High CD59 expression may contribute to the limited success of complement-activating monoclonal antibody therapies. Therefore, evaluating CD59 expression in tumors may help identify patients most likely to benefit from humoral immunotherapy.

Future therapeutic approaches may include:

  • Anti-CD59 monoclonal antibodies
  • Antisense oligonucleotides
  • Gene-silencing technologies
  • Small molecules targeting GPI-anchor biosynthesis
  • Combination therapies with complement-activating antibodies

Selective downregulation of CD59 on tumor cells could significantly enhance complement-mediated anti-tumor immunity and improve immunotherapeutic outcomes.